title: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.
abstract: A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.
authors.affiliation: Department of Pediatrics, University of Nebraska Medical Center, Omaha 68198.
authors.forename: E
authors.initials: E
authors.lastname: Bayever
authors.forename: P L
authors.initials: PL
authors.lastname: Iversen
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: J G
authors.initials: JG
authors.lastname: Sharp
authors.forename: H K
authors.initials: HK
authors.lastname: Tewary
authors.forename: M A
authors.initials: MA
authors.lastname: Arneson
authors.forename: S J
authors.initials: SJ
authors.lastname: Pirruccello
authors.forename: R W
authors.initials: RW
authors.lastname: Ruddon
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
authors.forename: G
authors.initials: G
authors.lastname: Zon
mesh_terms: D000293:Adolescent; D000328:Adult; D001483:Base Sequence; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013873:Thionucleotides / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D020319:Oligodeoxyribonucleotides, Antisense; D016376:Oligonucleotides, Antisense; D013873:Thionucleotides; D016159:Tumor Suppressor Protein p53; C086760:OL(1)p53